1800327-36-9

LEI105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor. Diacylglycerol lipase (DAGL)-α and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG).